[go: up one dir, main page]

WO2022239714A1 - Agent pour prévenir ou améliorer la nycturie, l'état de veille après l'endormissement, ou la miction fréquente - Google Patents

Agent pour prévenir ou améliorer la nycturie, l'état de veille après l'endormissement, ou la miction fréquente Download PDF

Info

Publication number
WO2022239714A1
WO2022239714A1 PCT/JP2022/019616 JP2022019616W WO2022239714A1 WO 2022239714 A1 WO2022239714 A1 WO 2022239714A1 JP 2022019616 W JP2022019616 W JP 2022019616W WO 2022239714 A1 WO2022239714 A1 WO 2022239714A1
Authority
WO
WIPO (PCT)
Prior art keywords
nocturia
preventive
improving
agent
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/019616
Other languages
English (en)
Japanese (ja)
Inventor
崇広 宮島
孝広 中田
理夏子 石橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobayashi Pharmaceutical Co Ltd
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Publication of WO2022239714A1 publication Critical patent/WO2022239714A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Definitions

  • the present invention relates to a preventive or ameliorating agent for nocturnal pollakiuria, a preventive or ameliorating agent for preventive or ameliorating agents, and a preventive or ameliorating agent for frequent urination.
  • Urination dysfunction includes frequent urination and nocturia, which are symptoms of increased frequency of urination.
  • Frequent urination also called daytime pollakiuria, is a symptom in which the frequency of urination is high between waking up in the morning and going to bed. Point.
  • nocturia generally refers to a symptom in which the number of times of urination is one or more on average after going to bed until waking up. Frequent urination and nocturia have different onset causes, and the two do not necessarily coexist, and many patients with nocturia are normal during the daytime.
  • the present invention provides inventions in the following aspects for use in preventing or improving frequent urination.
  • Item 3-1 An agent for preventing or improving frequent urination, containing ⁇ -mangostin.
  • Item 3-2 The preventive or ameliorating agent according to Item 3-1, which contains an extract and/or a processed product of mangosteen as ⁇ -mangostin.
  • Item 3-3 The preventive or ameliorating agent according to Item 3-1 or 3-2, which is used for preventing or ameliorating frequent urination caused by decreased bladder capacity.
  • Item 3-4 The preventive or ameliorating agent according to any one of Items 3-1 to 3-3, which is used for a person having symptoms of both urinary frequency and nocturia.
  • Item 3-5 An agent for preventing or improving frequent urination, containing ⁇ -mangostin.
  • Item 3-1 An agent for preventing or improving frequent urination, containing ⁇ -mangostin.
  • Item 3-2 The preventive or ameliorating
  • ⁇ -mangostin by using ⁇ -mangostin, it is possible to exhibit multiple effects of improving sleep disorders, improving bladder capacity, and improving nocturnal polyuria. It becomes possible to effectively prevent or improve wakefulness or frequent urination.
  • FIG. 10 is a diagram showing the results of calculating the average value of the scores for questions about the degree of difficulty.
  • nocturia refers to a symptom in which the frequency of urination is 1 or more on average from after going to bed until waking up, and a symptom of having to get up to urinate during sleep.
  • the term “urination stress” refers to stress such as worry (anxiety), annoyance, tension, pain, fatigue, malaise, irritation (irritation), depression (depressed mood), etc. due to the urge to urinate. .
  • agent for preventing or improving pollakiuria refers to an agent used to prevent the onset of pollakiuria, or to reduce, alleviate, or suppress the progression of symptoms of pollakiuria.
  • Specific examples of the form of the agent for preventing or improving nocturia of the present invention include food and drink and drugs for internal use (including quasi-drugs for internal use).
  • the preventive or ameliorating agent for nocturia of the present invention can exhibit an excellent improvement effect on nocturia in people with sleep disorders by taking and administering it for a short period of time.
  • the preventive or ameliorating agent for nocturia of the invention can be suitably used for preventing or ameliorating nocturia in people with sleep disorders.
  • "persons with sleep disorders” refer to those with a Pittsburgh Sleep Questionnaire total score (PSQIG) of less than 6.5.
  • the preventive or ameliorating agent for nocturia of the present invention for example, among those who are required to prevent or ameliorate nocturia, those who are concerned about urinary troubles such as frequent urination and urinary urgency, and urinary troubles It can be preferably applied to people who are concerned about going out due to anxiety, people who are concerned about urinary troubles due to aging, and people who are concerned about urinary troubles due to aging (for example, 40 years old or older).
  • the preventive or ameliorating agent for nocturia of the present invention can be used by those who require prevention or amelioration of nocturia, anxiety (anxiety), annoyance, etc. due to the urge to urinate, although it does not require treatment at a hospital or the like. It can also be preferably applied to healthy people who are stressed against.
  • the form of the preventive or ameliorating agent of the present invention include foods and beverages and drugs for internal use (including quasi-drugs for internal use).
  • the agent for preventing or improving nighttime awakening of the present invention is in the form of food
  • the type of food, the content of ⁇ -mangostin in the food, etc. are the same as in the case of "1.
  • Agent for preventing or improving nocturia is.
  • the agent for preventing or improving nighttime awakening of the present invention is in the form of an internal medicine
  • the type of internal medicine, the content of ⁇ -mangostin in the internal medicine, etc. are described in the above "1.
  • Prevention of nocturia. or improver are described in the above "1.
  • the preventive or ameliorating agent for awakening after awakening of the present invention is used for those who require prevention or amelioration of awakening during awakening.
  • the preventive or ameliorating agent for nocturnal awakening of the present invention can improve sleep quality by improving nocturnal awakening.
  • the preventive or ameliorating agent for nocturnal awakening of the present invention among those who are required to prevent or improve nocturnal awakening, those who are concerned about urinary troubles such as frequent urination and urinary urgency, and those who are concerned about urinary troubles. It can be preferably applied to people who are anxious about going out, people who are concerned about urinary troubles due to aging, and people who are concerned about urinary troubles due to aging (for example, 40 years old or older).
  • the preventive or ameliorating agent for nocturnal awakening of the present invention can be used for anxiety (anxiety), annoyance, etc. due to the urge to urinate, although it does not require treatment at a hospital or the like, among those who require prevention or improvement of nocturnal awakening. It can also be preferably applied to ordinary people who are feeling stressed.
  • the agent for preventing or improving pollakiuria of the present invention is used for those who require prevention or improvement of pollakiuria.
  • the subjects for application of the urinary preventive or ameliorating agent of the present invention may be mammals including humans, preferably humans.
  • Test Example 2 Verification of Orexin Receptor Blocking Activity It is known to improve sleep disorders. Therefore, in this test, the orexin receptor inhibitory activity of ⁇ -mangostin was evaluated.
  • DMEM medium containing 10% FBS
  • 10 nM orexin-B 10 nM orexin-B
  • the intracellular calcium concentration was determined using an intracellular calcium measurement kit.
  • the intracellular calcium concentration was determined under the same conditions as above, except that no sample was added.
  • the orexin receptor inhibitory activity was calculated according to the following formula. It is known that when the orexin receptor is stimulated by an agonist, it activates phospholipase C and hydrolyzes phosphatidylinositol, increasing the intracellular calcium concentration. , it can be said that the lower the intracellular calcium concentration measured in this test, the higher the orexin receptor inhibitory activity.
  • Test Example 3 Verification of Effect of Improving Bladder Capacity in Overactive Bladder Model Using an overactive bladder model, the effect of ⁇ -mangostin on improving bladder capacity was evaluated.
  • rats (7 weeks old, female, SD) were subjected to laparotomy under anesthesia, bilateral common iliac veins and bilateral uterine veins were ligated, and the bladder was made ischemic.
  • An overactive bladder model rat in which the bladder was in an overactive state was prepared by breeding the rats in this state for 14 days. From 14 days after the bladder ischemia treatment, 2 ml of a sample containing 160 mg/ml of ⁇ -mangostin was orally administered once a day, and the rats were fed under normal conditions for 14 days.
  • Test Example 4 Verification of Effect of Improving Nocturnal Polyuria in Acetic Acid-Induced Cystitis Model Using an acetic acid-induced cystitis model, the effect of ⁇ -mangostin in improving nocturnal polyuria was evaluated.
  • Test Example 5 Verification of the effect of improving nocturia and nocturia in humans 3 capsules containing the contents shown in Table 3 were given to 10 subjects complaining of nocturia (4 males, 6 females). (400 mg of ⁇ -mangosteen) was taken once a day for 4 weeks. The total number of awakenings during sleep and the total number of urination during sleep over the past one week were counted on the day before the start of capsule intake, 2 weeks after intake, and 4 weeks after intake. In addition, the Pittsburgh Sleep Questionnaire and Nocturia QOL Questionnaire (N-QOL) were completed on the day before the start of taking the capsules and 4 weeks after taking the capsules. In addition, the subjects of this study did not include those with sleep disorders caused by disturbances in body rhythms.
  • Test Example 6 Verification of Nocturia in Humans and Improvement of Frequent Urination 13 subjects (6 males, 7 females) complaining of nocturia were asked to answer the Pittsburgh Sleep Questionnaire. Subjects with a total score (PSQIG) of 6.5 or higher were "no sleep disorder group” (1 male, 6 females), and subjects with a total score of less than 6.5 were "with sleep disorder group” (5 males, 6 females). 1 female). In addition, the subjects in this study did not include those with sleep disorders caused by disturbances in body rhythms, and the group with sleep disorders was those with sleep disorders due to reasons other than disturbances in body rhythms.
  • PSQIG total score
  • Test Example 7 Verification of Nocturia in Humans and Improvement of Frequent Urination 3 capsules containing the contents shown in Table 3 were given to 13 subjects complaining of nocturia (6 males, 7 females). (400 mg of ⁇ -mangosteen) was taken once a day for 4 weeks. The subjects did not include those with prostatic hyperplasia. The total number of times of urination during sleep over the past week was counted on the day before the start of capsule intake, 2 weeks after the intake, and 4 weeks after the intake. In addition, they were asked to answer the nocturia QOL questionnaire (N-QOL) on the day before the start of taking the capsules and 4 weeks after taking the capsules.
  • N-QOL nocturia QOL questionnaire

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour but de fournir un agent pour prévenir ou améliorer la nycturie, un agent pour prévenir ou améliorer l'état de veille après l'endormissement, ou un agent pour prévenir ou améliorer la miction fréquente. La solution selon l'invention porte sur une α-mangostine qui peut présenter, en combinaison, une action d'amélioration sur les troubles du sommeil, une action d'amélioration sur la capacité de la vessie, et une action d'amélioration sur la polyurie nocturne, et qui peut être utilisée comme principe actif pour un agent pour prévenir ou améliorer la nycturie, un agent pour prévenir ou améliorer l'état de veille après l'endormissement, et un agent pour prévenir ou améliorer la miction fréquente.
PCT/JP2022/019616 2021-05-13 2022-05-09 Agent pour prévenir ou améliorer la nycturie, l'état de veille après l'endormissement, ou la miction fréquente Ceased WO2022239714A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021081823A JP7716225B2 (ja) 2021-05-13 2021-05-13 夜間頻尿、中途覚醒又は頻尿の予防又は改善剤
JP2021-081823 2021-05-13

Publications (1)

Publication Number Publication Date
WO2022239714A1 true WO2022239714A1 (fr) 2022-11-17

Family

ID=84029611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/019616 Ceased WO2022239714A1 (fr) 2021-05-13 2022-05-09 Agent pour prévenir ou améliorer la nycturie, l'état de veille après l'endormissement, ou la miction fréquente

Country Status (3)

Country Link
JP (1) JP7716225B2 (fr)
TW (1) TW202310829A (fr)
WO (1) WO2022239714A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047180A (ja) * 2000-08-02 2002-02-12 Lotte Co Ltd シクロオキシゲナーゼ阻害剤及びそれを含有する飲食品
JP2005295991A (ja) * 2004-03-18 2005-10-27 Sakamoto Yakusoen:Kk Ｐｐａｒ活性化作用を有する健康食品およびｐｐａｒ活性化剤
CN101406496A (zh) * 2007-10-12 2009-04-15 王莉 一种治疗前列腺炎及其它男性生殖系统疾病的配方
JP2010064992A (ja) * 2008-09-11 2010-03-25 Hayashibara Biochem Lab Inc ペルオキシソーム増殖剤応答性核内受容体α活性化剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047180A (ja) * 2000-08-02 2002-02-12 Lotte Co Ltd シクロオキシゲナーゼ阻害剤及びそれを含有する飲食品
JP2005295991A (ja) * 2004-03-18 2005-10-27 Sakamoto Yakusoen:Kk Ｐｐａｒ活性化作用を有する健康食品およびｐｐａｒ活性化剤
CN101406496A (zh) * 2007-10-12 2009-04-15 王莉 一种治疗前列腺炎及其它男性生殖系统疾病的配方
JP2010064992A (ja) * 2008-09-11 2010-03-25 Hayashibara Biochem Lab Inc ペルオキシソーム増殖剤応答性核内受容体α活性化剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DMITRIY OBOLSKIY, IVO PISCHEL, NISARAT SIRIWATANAMETANON, MICHAEL HEINRICH: "Garcinia mangostana L.: a phytochemical and pharmacological review", PHYSIOTHERAPY RESEARCH, vol. 23, no. 8, 1 August 2009 (2009-08-01), GB , pages 1047 - 1065, XP055314186, ISSN: 0951-418X, DOI: 10.1002/ptr.2730 *

Also Published As

Publication number Publication date
JP2022175444A (ja) 2022-11-25
TW202310829A (zh) 2023-03-16
JP7716225B2 (ja) 2025-07-31

Similar Documents

Publication Publication Date Title
US7335651B2 (en) Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation
US20120052138A1 (en) Composition comprising green tea extract
JP6898905B2 (ja) インドナガコショウ抽出物を含む排尿障害の予防、治療及び改善用組成物
Hasan et al. Effect of fenugreek on type 2 diabetic patients
Said et al. Weight loss in animals and humans treated with “weighlevel”, a combination of four medicinal plants used in traditional arabic and islamic medicine
KR101189108B1 (ko) 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물
KR101511364B1 (ko) 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물
CN105943958A (zh) 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法
JP7716225B2 (ja) 夜間頻尿、中途覚醒又は頻尿の予防又は改善剤
WO2016167855A1 (fr) Association d'albutérol et de caféine pour le traitement synergique de l'obésité ou de la sarcopénie
US20070122502A1 (en) Therapeutic juice composition for women
US20100151066A1 (en) Composition for suppressing appetite, improving tone and mood, with a natural antidepressant activity and with an antiasthenic effect
US11628153B2 (en) Agent for preventing or amelioriting nocturia
JPWO2002060457A1 (ja) 抗ストレス剤
RU2361599C1 (ru) Фармацевтическая композиция, обладающая седативным и анксиолитическим действием
Strupler et al. 10 Medical Issues, Pharmacology and Nutrient Interactions
CN106798826A (zh) 麦冬寡糖在制备促进棕色脂肪生成药物中的应用
KR20250086335A (ko) 현초 추출물을 포함하는 항비만 조성물
WO2019009354A1 (fr) Composition pour l'amélioration de la dysurie
JP2023085993A (ja) 精神的ストレスの予防又は改善剤
KR20230005819A (ko) 수면의 질의 개선제
Roxburgh Organotherapy
CN109662167A (zh) 一种含葫芦茶减肥茶及其制备方法
CN107509833A (zh) 一种含葫芦茶减肥茶及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22807416

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22807416

Country of ref document: EP

Kind code of ref document: A1